Factory 99% Niraparib Powder CAS 1038915-60-4 Chemical Intermediate Niraparib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A1000
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Niraparib
• CAS: 1038915-60-4
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Niraparib
Appearance	White Powder
CAS NO.	1038915-60-4
Storage	Keep in a cool, dry, dark location

 

Niraparib is a highly potent, selective inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes, specifically targeting PARP-1 and PARP-2. It disrupts DNA repair mechanisms in cancer cells by inducing PARP-DNA complexes, leading to synthetic lethality, particularly in tumors with homologous recombination deficiencies (e.g., BRCA1/2 mutations).

 

1. Ovarian Cancer Maintenance: Approved for first-line or recurrent ovarian, fallopian tube, or primary peritoneal cancer in patients who have responded to platinum-based chemotherapy, regardless of BRCA mutation status.
2. HRD-Positive Tumors: Used in combination with other therapies for advanced solid tumors exhibiting homologous recombination deficiency.
3. BRCA-Mutated Breast Cancer: Investigated in clinical trials for metastatic breast cancer with germline BRCA mutations.

1. DNA Damage Accumulation: By inhibiting PARP, Niraparib prevents base excision repair, causing replication fork collapse and double-strand breaks in cancer cells reliant on homologous recombination for survival.
2. Targeted Cytotoxicity: Exploits "BRCAness" phenotypes, selectively killing tumor cells while sparing normal tissues with intact DNA repair pathways.
3. Enhanced Chemosensitivity: Potentiates platinum-based and DNA-damaging agents by amplifying unrepaired DNA lesions, improving treatment outcomes in responsive populations.